Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155656 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Sudipta Naskar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: sdiptaa@gmail.com. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, MicroRNAs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: MicroRNAs (MIRs) play a crucial role in colorectal cancer (CRC) development and metastasis by regulating immune responses. Tumour-infiltrating lymphocytes (TILs) are an important predictive factor in many cancers, but, their association with microRNAs have not been studied well in colorectal cancer. Three microRNAs (MIR34A, MIR31 & MIR21), the roles of which in tumorigenesis is well-studied and which also possess immunomodulatory effect, were identified by extensive literature search. Of these, MIR34A acts as a tumour suppressor, MIR21 is considered an onco-MIR, and MIR31 displays both tumour-suppressing and oncogenic properties, making it ambiguous. This study examines the relationship between these three micro-RNAs and TILs in CRC. MATERIALS & METHODS: Conducted over 18 months at a tertiary cancer care hospital in southern India, this unicentric observational study included 69 cases. These cases were analyzed for miR expression using q-RT-PCR, TILs density through hematoxylin & eosin(H&E) slide examination, and p53 and beta-catenin expression via immunohistochemistry (IHC). Correlations between non-parametric variables were assessed using Chi-square and Spearman correlation tests. RESULTS: The study found significantly higher MIR34A expression in patients aged 60 years and less (26/41, p=0.024) and a higher prevalence of MIR21 in male patients (23/35, p=0.012). TILs at the tumour advancing front were categorized as low (≤10 %) or high (≥15 %). Among the 36 cases with low TILs, high MIR34A and high MIR31 expressions were observed in 24 cases (p=0.016) and 23 cases (p=0.03), respectively. Conversely, 21 of 33 cases with high TILs had low expressions of both MIR34A and MIR31. High TILs were more common in early-stage CRC (TNM stages I-IIIA), with 20 out of 28 cases, compared to 28 of 41 cases in later stages (IIIB-IVC) exhibiting low TILs (p=0.003). Aberrant p53 expression correlated with lower MIR34A levels, consistent with TCGA data. CONCLUSION: Lower MIR34A and MIR31 levels are associated with higher TILs density in CRC. Unlike other cancers where MIR34A has anti-tumour effects, there was no statistically significant correlation between its expression and the pT or TNM stages in this study. Increased TILs being a good prognostic indicator, this suggests MIR34A and MIR31 may help CRC cells evade immune surveillance. Aberrant p53 expression downregulates MIR34A, underscoring the therapeutic potential of miRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: sdiptaa@gmail.com.
- Department of Surgical Oncology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: drimishra13@gmail.com.
- Department of Surgical Oncology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: dr.bssrinath@sschrc.org.
- Department of Histopathology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: rekha_v_kumar@yahoo.co.in.
- Department of Molecular Oncology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: durga.devi@ssnccpr.org.
- Department of Molecular Oncology, Sri Shankara Cancer Hospital & Research Centre, Bangalore, India. Electronic address: pooja.melgiri@gmail.com.
Zitieren
APA
Naskar, S., Mishra, I., Srinath, B. S., Kumar, R. V., Veeraiyan, D., Melgiri, P., P S, H., Sastry, M., K, V., & Korlimarla, A. (2024). Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155656
Vancouver
Naskar S, Mishra I, Srinath BS, Kumar RV, Veeraiyan D, Melgiri P, et al. Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155656
BibTeX
@article{Naskar2024,
author = {Naskar, Sudipta and Mishra, Ipseet and Srinath, B S and Kumar, Rekha V and Veeraiyan, Drugadevi and Melgiri, Pooja and P S, Hari and Sastry, Manjunath and K, Venkatachala and Korlimarla, Aruna},
title = {Lower expressions of MIR34A and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155656}
}
EUVIMED